| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| ClinicalTrials.gov Identifier: | NCT00058903 |
Purpose
The goal of this study is to find an effective and well-tolerated medical therapy for itching due to liver disease. Persons with primary biliary cirrhosis or chronic hepatitis C are currently being enrolled in the study. Persons participating in the study are given sertraline, a medication which is also often used for depression,to treat their itching. The dose is gradually increased as the effect on itching and any other potential side effects are carefully monitored.
| Condition | Intervention | Phase |
|
Pruritus Liver Cirrhosis, Biliary Hepatitis C |
Drug: sertraline |
Phase II |
| MedlinePlus related topics: | Cirrhosis Hepatitis Hepatitis C Itching |
| Drug Information available for: | Sertraline hydrochloride Sertraline |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Treatment of Cholestatic Pruritus With Sertraline |
Eligibility
| Ages Eligible for Study: | 21 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations More Information
| Study ID Numbers: | TRCPWS |
| First Received: | April 14, 2003 |
| Last Updated: | October 9, 2007 |
| ClinicalTrials.gov Identifier: | NCT00058903 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
